e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants? [PDF]
Leukemia, 2005 DEMEHRI S +12 more
openaire +2 more sources
Targeting HSPA8 to repress GPX4 and induce ferroptosis in BCR-ABL positive leukemia
Biomedical TechnologyBCR-ABL positive (BCR-ABL+) leukemia is driven by constitutive activation of tyrosine kinase activity, with tyrosine kinase inhibitors (TKIs) serving as the standard treatment. However, resistance to TKIs remains a significant clinical challenge. In this
Shuxin Zhong +12 more
doaj +1 more source
Direct genetic demonstration of Gα13 coupling to the orphan G protein-coupled receptor G2A leading to RhoA-dependent actin rearrangement [PDF]
, 2000 G2A is an orphan G protein-coupled receptor (GPCR), expressed predominantly in T and B cells and homologous to a small group of GPCRs of unknown function expressed in lymphoid tissues.
Feramisco, Jamison D. +6 more
core
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. [PDF]
, 2011 Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with leukaemia driven by BCR-ABL1 (ref. 1) and other oncogenic tyrosine kinases. Recent efforts have focused on developing more potent TKIs that also inhibit mutant tyrosine kinases ...
Braig, Melanie +22 more
core
MicroRNAs act as decoy molecules to inhibit the function of RNA binding proteins [PDF]
, 2008 Professional Biological Sciences: 3rd Place (The Ohio State University Edward F. Hayes Graduate Research Forum)Altered microRNA (miRNA) expression contributes to aberrant post-transcriptional gene regulation in several types of cancers; however, their ...
Eiring, Anna M.
core
Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS [PDF]
, 2011 The LC-ESI-MS was developed and validated for the analysis of imatinib in plasma and bone marrow samples using deuterated imatinib (D(8)-IM) as an internal standard. The biological samples were extracted using Strata-X-C SPE cartridges and separated on C&
Elliott, M. +4 more
core +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem +19 more
core +1 more source
Molecular mechanisms in haematological malignancies [PDF]
, 2009 Haematopoiesis requires the constant production of large numbers of peripheral blood cells. This process is under tight control of transcription factor networks as well as cytokines, growth factors and hormones.
Avellino, Roberto +2 more
core
Chronic Myeloid Leukemia with Rare e1a3 BCR-ABL Transcript
Pakistan Journal of Medicine and DentistryChronic myelogenous leukemia (CML) results from neoplastic transformation of a hematopoietic stem cell. It is cytogenetically characterized by the presence of Philadelphia chromosome which results from reciprocal translocation t(9;22) that juxtaposes ...
Najia Tabassum +3 more
doaj